Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ascentage Starts Trial of MDM2-p53 Inhibitor in Hematologic Malignancies

publication date: Jul 22, 2020

Ascentage Pharma of Suzhou has begun dosing patients in a China Phase Ib trial of APG-115, its novel MDM2-p53 inhibitor, to treat hematologic malignancies. It is already being tested in solid tumors. APG-115 is an oral, selective, small-molecule inhibitor of the MDM2-p53 protein-protein interaction. The candidate will be studied as a single agent or paired with azacitidine or cytarabine for r/r acute myeloid leukemia or high risk myelodysplastic syndrome. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital